Search
olodaterol/tiotropium (Stiolto Respimat)
Indications:
- COPD
Dosage:
- once-daily oral inhalation spray
Adverse effects:
- nasopharyngitis
- cough
- back pain
General
pharmacologic combination
inhalation agent (inhalant)
References
- Lowes R
FDA Approves Stiolto Respimat for COPD
Medscape Oncology. May 26, 2015
http://www.medscape.com/viewarticle/845398
- Boehringer Ingelheim PR Newswire. May 26, 2015
FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation
Spray as Once-Daily Maintenance Treatment for COPD.
http://www.prnewswire.com/news-releases/fda-approves-boehringer-ingelheims-stiolto-respimat-inhalation-spray-as-once-daily-maintenance-treatment-for-copd-300088485.html
Components
olodaterol (Striverdi Respimat)
tiotropium (Spiriva, Respimat)